The short version of Thymosin fraction 5 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-10. Anything still debated is marked as such rather than presented as settled.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈3,108 Da | Synthetic 28-residue peptide |
| Amino acid count | 28 | N-terminal serine carries an acetyl group |
| Appearance | White to off-white powder | Lyophilized solid |
| Water solubility | Freely soluble | Dissolves in aqueous buffer |
| Common synonyms | Thymalfasin; Tα1 | Thymalfasin is the international nonproprietary name |
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Thomas, a solicitor from Tenterfield, New South Wales, had been retained to defend Maj. Lenahan. The night before, however, he agreed to represent all six defendants. The "Visser Incident" was the first case to go to trial. Lt. Morant's former orderly and interpreter, BVC Trooper Theunis J. Botha, testified that Visser, who had been promised his life would be spared, was cooperative during two days of interrogation and his information was found to have been true. Despite this, Morant ordered him shot. In response, Morant testified that he only followed orders to take no prisoners as relayed to the late Captain Hunt by Col. Hubert Hamilton. He alleged that Visser was captured wearing a British Army jacket and that Hunt's body had been mutilated. In response, the court moved to Pretoria, where Col. Hamilton testified that he had "never spoken to Captain Hunt with reference to his duties in the Northern Transvaal". Though stunned, Maj. Thomas argued that his clients were not guilty because they believed that they "acted under orders". In response, Bolton argued that they were "illegal orders" and said, "The right of killing an armed man exists only so long as he resists; as soon as he submits he is entitled to be treated as a prisoner of war." The Court ruled in Bolton's favor. Morant was found guilty of murder. Handcock, Witton, and Picton were convicted of the lesser charge of manslaughter. On 27 February Morant and Handcock were executed by firing squad after being convicted of murdering eight Afrikaner POWs.
== Experimental validation == IDPs can be validated in several contexts. Most approaches for experimental validation r and of IDPs are restricted to extracted or purified proteins. Some new experimental strategies aim to explore in vivo conformations and structural variations of IDPs inside intact living cells and systematic comparisons between their dynamics in vivo and in vitro. (In the study of IDPs, the term in vivo is used a little differently from the ordinary meaning of in vivo: it refers to the state as found in living cells, not necessarily the entire living organism, as opposed to the traditional cell-free method of study.)
The insulin/IGF/relaxin family is a group of evolutionarily related proteins which possess a variety of hormonal activities. In humans, these proteins are divided into two subsets: 1) insulin and insulin-like growth factors 2) relaxin family peptides:
Winning percentage: 70.5% at International circuit & 78.9% at National circuit Podium percentage: 86.9% at International circuit & 94.7% at National circuit Top 5 percentage: 95.1% at International circuit & 100.0% at National circuit
== Treatment == Because of the unclear pathogenesis and pathophysiology of Tarlov cysts, there is no consensus on the optimal treatment of symptomatic sacral perineural cysts. Patients often choose to pursue treatment when the progression of neurological deficits seriously impacts their quality of life. Since cysts are innervated, micro fenestration and surgical sleeving of the cysts to diminish the amount of accumulated cerebrospinal fluid and decrease compression of the spine and spinal nerves has been successful in a number of patients. The cysts are carefully separated enough from surrounding tissue to be wrapped with fatty tissue or pericardial biomaterial to excise the fluid from the cyst. If the cyst does not drain spontaneously, then it is drained and patched using a biosynthetic dural patch. The use of this technique is done in the U.S. and is spreading in Europe but recovery is generally extensive. Micro fenestration alone has been done with some success in Asia. A biopolymer plate is also being used experimentally to strengthen a sacrum thinned by cystic erosion. The risks of CSF leakage are higher on patients that have bilateral cysts on the same spinal level or clusters of cysts along multiple vertebrae, but immediate recognition of the leakage and repair can mitigate that risk. Various treatment methods have been tried in the past, including the extraction of cerebrospinal fluids from the cyst, fibrin glue injection and the complete or partial removal of cyst.
Sources: en.wikipedia.org
=== Mid-infrared === With the advent of cheap microcomputers it became possible to have a computer dedicated to controlling the spectrometer, collecting the data, doing the Fourier transform and presenting the spectrum. This provided the impetus for the development of FTIR spectrometers for the rock-salt region. The problems of manufacturing ultra-high precision optical and mechanical components had to be solved. A wide range of instruments are now available commercially. Although instrument design has become more sophisticated, the basic principles remain the same. Nowadays, the moving mirror of the interferometer moves at a constant velocity, and sampling of the interferogram is triggered by finding zero-crossings in the fringes of a secondary interferometer lit by a helium–neon laser. In modern FTIR systems the constant mirror velocity is not strictly required, as long as the laser fringes and the original interferogram are recorded simultaneously with higher sampling rate and then re-interpolated on a constant grid, as pioneered by James W. Brault. This confers very high wavenumber accuracy on the resulting infrared spectrum and avoids wavenumber calibration errors.
1989 – Ludolf Krehl Prize, awarded by the Southwest German Society of Internal Medicine (for her dissertation) 2003 – Carus Medal, awarded by the German National Academy of Sciences Leopoldina 2010 – Rudolf Leuckart Medal, awarded by the German Society for Parasitology (for her work on energy metabolism in pathogenic parasites such as the malaria pathogen)
European Union officials, European ministers and Commissioner (Tonio) Borg set up an urgent meeting in Brussels on 13 February 2013 on how to contain the horse meat scandal that exposed flaws in European control systems on food safety, and to formulate an action plan. Following the meeting, EU agriculture ministers announced a three-month coordinated control plan of DNA testing of processed meat across the European Union. The plan, adopted 19 February 2013, called for 2,500 random tests on processed food for horse DNA and 4,000 for phenylbutazone (bute), beginning in March 2013, with initial results announced on 15 April 2013. The Hague-based Europol would handle the co-ordination of investigations among national authorities, as well as any raids on premises and arrests on suspicion of criminal conspiracy to defraud.
Boron (5B) naturally occurs as isotopes 10B and 11B, the latter of which makes up about 80% of natural boron. There are 13 radioisotopes that have been discovered, with mass numbers from 7 to 21, all with short half-lives, the longest being that of 8B, with a half-life of only 771.9(9) ms and 12B with a half-life of 20.20(2) ms. All other isotopes have half-lives shorter than 17.35 ms. Those isotopes with mass below 10 decay into helium via short-lived isotopes of beryllium while those with mass above 11 mostly become carbon.
Sources: en.wikipedia.org
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.
It is usually described as an immunomodulatory peptide rather than a classic hormone. It acts on immune cells through receptor pathways. No single endocrine organ target defines its function.
Several countries, including Italy and China, allow it for specific indications. The FDA has not approved it as a drug in the United States. Availability depends on local regulation.
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.